<DOC>
	<DOC>NCT00220428</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of T-cell vaccination in MS patients.</brief_summary>
	<brief_title>T-Cell Vaccination in Multiple Sclerosis (MS)</brief_title>
	<detailed_description>Immunization of MS patients with irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones. Clinical immunologic and neuroradiologic evaluation.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Definite MS (post criteria) Relapsing remitting or primary progressive clinical course. At least one relapse in the last two years. Disease duration &gt; 1 year Expanded Disability Status Scale (EDSS) between 06 Brain magnetic resonance imaging (MRI) compatible with MS Not involved in any other clinical trials No other systemic disease Does not comply with the above</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>T cell</keyword>
</DOC>